Recent Press Releases

RFS Pharma Announces a 2 log Plasma Viral Load Decline Following 10 Day Treatment with a Dual Combination of Amdoxovir® (DAPD) and Retrovir® (AZT) in HIV-1 Infected Individuals.

02/06/2008

Full Text

CONTACT: RFS Pharma, LLC    Judy Mathew

+1 404 601-1430 x1416       SOURCE: RFS Pharma, LLC

RFS Pharma Appoints Vice President of Clinical Operations to Lead Clinical Development of Amdoxovir

01/02/2008

Full Text

CONTACT: RFS Pharma, LLC    Judy Mathew

+1 404 601-1430 x1416       SOURCE: RFS Pharma, LLC

RFS Pharma, LLC and Genoscience Pharma Sign Joint Venture Agreement to Discover and Develop Protease Inhibitors

06/19/2007

Full Text

CONTACT: RFS Pharma, LLC    Judy Mathew

+1 404 601-1430 x1416       SOURCE: RFS Pharma, LLC

RFS Pharma, LLC Awarded NIH Grant to Develop
Resistance Repellent Anti-HIV Drugs

05/30/2007

Full Text

CONTACT: RFS Pharma, LLC    Judy Mathew

+1 404 601-1430 x1416       SOURCE: RFS Pharma, LLC

RFS Pharma, LLC Announces ACLIRES
International Ltd. to Conduct Phase 2 HIV Study

10/04/2006

Full Text

CONTACT: RFS Pharma, LLC    Judy Mathew

+1 404 601-1430 x1416       SOURCE: RFS Pharma, LLC

RFS Pharma Announces Appointment of Dr. Steven J.
Coats as Senior Director of Chemistry  

05/07/2006

Full Text

CONTACT: RFS Pharma, LLC    Judy Mathew

+1 404 601-1430 x1416       SOURCE: RFS Pharma, LLC

RFS Pharma Announces 2-Week Data from an NIH-
Sponsored Phase 2 Clinical Trial Evaluating
Amdoxovir^® (AMDX) in Highly Treatment-
Experienced HIV-1 Infected Individuals  

02/14/2006

Full Text

CONTACT: RFS Pharma, LLC    Judy Mathew

+1 404 601-1430 x1416       SOURCE: RFS Pharma, LLC